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Letter to the EditorAssessment of a causal relationship
between body mass index and atopic
dermatitisTo the Editor:
Atopic dermatitis (AD) is an itchy, inflammatory skin condition
associated with multiple comorbidities. Observational epidemi-
ology suggests an increased prevalence of obesity in patients with
AD, but (1) whether there is a causal effect and (2) whether
obesity leads to AD or vice versa remain unclear. Genetic predis-
position to obesity has been shown to promote psoriasis,1 but
dermatologic disorders can also lead to reduced participation in
physical activity, resulting in weight gain. We aimed to investi-
gate evidence of causality in the association of AD with elevated
body mass index (BMI).
We meta-analyzed 33 published studies examining the associ-
ation between obesity or elevated BMI and AD to summarize
available observational data (see Fig E1 in this article’s Online
Repository at www.jacionline.org). The odds ratio (OR) for AD
in overweight individuals was 1.05 (95% CI 5 0.94-1.19) in
adults (n 5 51,008) and 1.08 (95% CI 5 1.00-1.16) in children
(n 5 506,202) (see Fig E2 in this article’s Online Repository at
www.jacionline.org). For obese individuals, the OR for having
AD was 1.19 (95% CI 5 0.95-1.49) in adults (n 5 1,400,679)
and 1.20 (95% 5 CI 1.11-1.30) in children (n 5 796,514) (see
Fig E3 in this article’s Online Repository at www.jacionline.
org); the methods and results are detailed in the Methods and
Results sections of the Online Repository (at www.jacionline.
org). We extended the observational analysis by using 2 large
population-based studies from the United Kingdom and
Norway2,3 (for details, see the Online Repository and Tables
E1-E4). Among overweight individuals (BMI of 25-30 kg/m2),
the OR of AD was 1.02 per each 1-kg/m2 increase in BMI
(95%CI5 1.00-1.04;P5 .07; 4,820 cases and 130,776 controls);
a similar estimate was found among obese individuals (BMI >30
kg/m2) (ie, OR51.02 [95% CI5 1.01-1.03; P5 3.33 10–4] in a
sample of 2,741 cases and 73,907 controls) (see Fig E4 in this
article’s Online Repository at www.jacionline.org).
Observational epidemiology has several limitations, including
bias from confounding and reverse causation; this restricts its
utility for causal inference. However, causality and the direction
of effect can be investigated by mendelian randomization (MR).
MR uses genetic variants as a proxy for the exposure (eg, BMI) to
estimate the effect on an outcome (eg, AD). Genetic variants are
randomly allocated at fertilization, therefore avoiding confound-
ing; they are not affected by outcomes later in life, thus avoiding
reverse causation. Genome-wide association studies (GWASs)
have identified single-nucleotide polymorphisms (SNPs) associ-
ated with BMI (<_941 loci4,5) and AD (24 loci in European popu-
lations6). These SNPs can be combined into a genetic risk score
(GRS) or ‘‘genetic instrument’’ that acts as a proxy for the spec-
ified trait during MR. 2020 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY li-
cense (http://creativecommons.org/licenses/by/4.0/).We conducted MR analysis by using data from the largest
population-based studies in the United Kingdom (UK Biobank2)
and Norway (Nord-Trøndelag Health Study, Norway3 [HUNT,
2006-08]) along with the largest published GWASs for BMI4,5
and AD6 to date, representing a total of 742,611 individuals
(see Table E5 in this article’s Online Repository at www.
jacionline.org). One-sample MR was performed in the UK
Biobank and HUNT data sets with the individuals’ BMI SNPs,
measured BMI, and AD status. Two-sample MR using published
GWAS data4-6 was performed and meta-analyzed with the
1-sample estimate to obtain an overall causal estimate. Similarly,
reverse MRwas conducted to investigate the effect of AD genetic
risk on BMI. Methodologic details and sensitivity analysis are
described in the Online Repository, including Fig E5.
The BMI GRS was strongly associated with BMI in both the
UK Biobank and HUNT data sets (see Figs E6 and E7 in this ar-
ticle’s Online Repository at www.jacionline.org), supporting its
use as a genetic instrument. Potential confounders of the GRS-
BMI association were detected (see Figs E6-E9), but the
magnitudes were minimal in comparison with the strength of as-
sociation with BMI. Similarly, the AD GRS was a good predictor
of AD in both the UKBiobank (OR5 1.26 [95%CI5 1.23-1.28];
F-statistic 5 2036; R2 5 0.7%) and HUNT (OR 5 1.15 [95%
CI 5 1.11-1.21]; F-statistic 5 97; R2 5 0.4%) data sets, despite
lacking an FLG null genotype (R501X/rs61816761), which is
known to show strong association with AD.
Meta-analyzed 1- and 2-sample MRs show evidence of a small
causal effect of higher BMI increasing the risk of AD (OR5 1.02
[95% CI 5 1.00-1.04]; P 5 .03) (Fig 1). This represents an in-
crease in AD risk by approximately 2% for each 1-kg/m2 increase
in BMI, which is remarkably similar to the observational estimate
(see Figs E2 and E3 in the Online Repository). Importantly, sensi-
tivity analyses showed little evidence of pleiotropy (for details,
see the Sensitivity Analysis section, Table E6, Fig E10, and
Fig E11 in this article’s Online Repository at www.jacionline.
org) or heterogeneity among the individual SNP effect estimates
(UK Biobank Q 5 101.07 [P 5 .32]; HUNT Q 5 100.04
[P 5 .37]). Two-sample MR using the larger number of recently
published BMI SNP estimates (941 SNPs)4 gave similar evidence
of a causal effect on AD risk (OR5 1.08 [95% CI5 1.01-1.16];
P 5.02).
In the reverse direction, meta-analysis gaveweak evidence of a
very small causal effect (Fig 2): a 0.03-kg/m2 change in BMI per
doubling odds of AD (95% CI 5 –0.02 to 0.08; P 5 .24). There
was little evidence of pleiotropy but modest heterogeneity among
the individual SNP effects (see Fig E12 and Table E7 in in this ar-
ticle’s Online Repository at www.jacionline.org). The difference
in BMI between patients with AD and controls estimated in
1-sample MR (0.15 kg/m2, 95% CI -1.97 to 2.27) was small
compared with observational estimates (see Tables E1 and E2),
indicating that the association is mainly explained by the causal
effect of BMI on AD.
The association of obesity with cardiometabolic disease and
systemic inflammation is now well recognized, and clinical
guidelines recommend screening patients with psoriasis for
obesity. The presence of a causal effect and the direction of effect
are both clinically relevant, to define a primary target (ie, obesity)
for intervention. Our MR analysis shows evidence that higher1
FIG 1. MR analysis of the causal effect of BMI on AD. Meta-analysis of 1-sample and 2-sample MR estimates
using individual BMI SNPs as instruments. Estimates are given per 1-kg/m2 increase in BMI.
FIG 2. Reverse direction MR analysis: effect of AD genetic risk on BMI. Meta-analysis of 1-sample and
2-sample MR estimates using individual AD SNPs as instrumental variables. Estimates represent change in
BMI (kg/m2) per doubling odds of AD.
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each 1-kg/m2 increase in BMI). Conversely, there was no strong
evidence of a causal effect of AD genetic risk on BMI; the esti-
mate of 0.03 kg/m2 suggests that genetic risk for AD has little
meaningful influence on an individual’s BMI. These findings
may be compared with the causal effect of BMI on psoriasis
and lack of effect of psoriasis genetic risk on BMI.1 The effect
of BMI onAD ismoremodest than the effect size observed in pso-
riasis, but the high prevalence of obesity (in more than one-third
of US adults) and AD (in <_10% of adults) demonstrate the poten-
tial importance of this causal effect on a population scale.
The molecular mechanisms by which obesity contributes to
skin inflammation remain unclear. Excess adipose tissue secretes
proinflammatory cytokines and hormones,7 and atopic inflamma-
tion may be promoted by disruption of the epidermal barrier in
obese individuals.8 Changes in the adipocytes and lymphatic ves-
sels may also contribute to obesity-related skin inflammation.8
Research to definemechanisms underlying the causal relationship
demonstrated by MR may identify novel therapeutic targets.
OurMR analyses have various strengths as well as weaknesses.
The large sample size is powerful, and the genetic instruments are
strong. The 2-sample analysis included an overlap of data sources
(from the HUNT study), which has the potential to bias the causal
estimate, but this bias would be in the direction of the null. Thereis the possibility of misclassification of AD, and because
AD often shows remission in childhood, this phenotype may
be particularly susceptible to recall bias in adult studies;
however, this would likely drive any estimate toward the null. It
is also important to note that the MR methodology applied here
does not define temporal relationship. Genetic risk has a lifetime
effect and therefore predates disease onset, but a causal effect
determined by MR does not rely on obesity occurring before the
onset of AD. However, when we attempted to mitigate this issue
by repeating the MR analyses using SNPs that are strongly
associated with childhood BMI,9 a causal estimate with the same
direction of effect was obtained (OR 5 1.04; 95% CI 5 1.01-
1.07; P 5 .01). Nevertheless, replication of these analyses
within pediatric cohorts with large sample sizes would be valu-
able future work.
In conclusion, we have found evidence of a small but
potentially important causal effect of BMI on AD. Clinical trials
have shown that interventions to promote weight loss can lead to
improvement in psoriasis, but this approach has not been tested in
AD. The results of our study provide support for the investigation
of obesity management strategies and/or targeting of the
adipocyte-keratinocyte cross-talk as therapeutic opportunities
for AD. This may contribute to the prevention of AD, as well as
to a reduction in the population prevalence of this chronic disease.
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LETTER TO THE EDITORThis research was conducted by using data from the UK Biobank Resource
(application number 10074) and the Nord-Trøndelag Health Study (the HUNT
Study). Details of patient and public involvement in the UK Biobank are
available online (http://www.ukbiobank.ac.uk/about-biobank-uk/ and https://
www.ukbiobank.ac.uk/wp-content/uploads/2011/07/Summary-EGF-consultati
on.pdf?phpMyAdmin5trmKQlYdjjnQIgJ%2CfAzikMhEnx6). The UK Bio-
bank data set used to conduct the research in this article is available via applica-
tion directly to the UK Biobank. Applications are assessed for meeting the
required criteria for access, including legal and ethics standards. More informa-
tion regarding data access can be found at the following website: http://www.
ukbiobank.ac.uk/scientists-3/. Data from the HUNT Study used in research pro-
jects will, when reasonably requested by others, be made available on request to
the HUNT Data Access Committee (hunt@medisin.ntnu.no). The HUNT data
access information (available at: http://www.ntnu.edu/hunt/data) describes in
detail the policy regarding data availability. No patients were specifically
involved in setting the research question or the outcome measures, nor were
they involved in developing plans for recruitment, design, or implementation
of this study. No patients were asked to advise on interpretation or writing up
of results. There are no specific plans to disseminate the results of the research
to study participants, but the UKBiobank and the HUNT Study disseminate key
findings from projects on their websites. The HUNT Study is a collaboration be-
tween HUNT Research Centre (Faculty of Medicine and Health Sciences,
NTNU, Norwegian University of Science and Technology), Nord-Trøndelag
CountyCouncil, Central NorwayRegionalHealthAuthority, and theNorwegian
Institute of Public Health. We acknowledge the permission of the EAGLE con-
sortium (including 23andMe) to use results from their previous GWAS of AD
(Paternoster et al6).
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